JP2014512369A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014512369A5 JP2014512369A5 JP2014505179A JP2014505179A JP2014512369A5 JP 2014512369 A5 JP2014512369 A5 JP 2014512369A5 JP 2014505179 A JP2014505179 A JP 2014505179A JP 2014505179 A JP2014505179 A JP 2014505179A JP 2014512369 A5 JP2014512369 A5 JP 2014512369A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- gdnf variant
- human gdnf
- human
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161474024P | 2011-04-11 | 2011-04-11 | |
| US61/474,024 | 2011-04-11 | ||
| PCT/US2012/031927 WO2012141936A1 (en) | 2011-04-11 | 2012-04-03 | Variants of human gdnf |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014512369A JP2014512369A (ja) | 2014-05-22 |
| JP2014512369A5 true JP2014512369A5 (enExample) | 2015-04-23 |
| JP6093345B2 JP6093345B2 (ja) | 2017-03-08 |
Family
ID=45932578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014505179A Active JP6093345B2 (ja) | 2011-04-11 | 2012-04-03 | ヒトｇｄｎｆの変異体 |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US9243046B2 (enExample) |
| EP (1) | EP2696889B1 (enExample) |
| JP (1) | JP6093345B2 (enExample) |
| KR (1) | KR101554799B1 (enExample) |
| CN (1) | CN103635201B (enExample) |
| AU (1) | AU2012243178B2 (enExample) |
| BR (1) | BR112013026004B1 (enExample) |
| CA (1) | CA2833158C (enExample) |
| CY (1) | CY1119750T1 (enExample) |
| DK (1) | DK2696889T3 (enExample) |
| EA (1) | EA025129B1 (enExample) |
| ES (1) | ES2656020T3 (enExample) |
| HR (1) | HRP20171993T1 (enExample) |
| HU (1) | HUE036239T2 (enExample) |
| IL (1) | IL228102A (enExample) |
| LT (1) | LT2696889T (enExample) |
| ME (1) | ME02849B (enExample) |
| MX (1) | MX337206B (enExample) |
| NO (1) | NO2696889T3 (enExample) |
| PL (1) | PL2696889T3 (enExample) |
| PT (1) | PT2696889T (enExample) |
| RS (1) | RS56639B1 (enExample) |
| SG (1) | SG193483A1 (enExample) |
| SI (1) | SI2696889T1 (enExample) |
| TW (1) | TWI583698B (enExample) |
| UA (1) | UA112981C2 (enExample) |
| WO (1) | WO2012141936A1 (enExample) |
| ZA (1) | ZA201306556B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017263174A1 (en) | 2016-05-13 | 2018-12-13 | Instituto de Medicina Molecular João Lobo Antunes | Methods of treating diseases associated with ILC3 cells |
| ES3036928T3 (en) * | 2019-12-19 | 2025-09-25 | Transfert Plus Soc En Commandite | Use of glial cell line-derived neurotrophic factor (gdnf) for the treatment of enteric neuropathies |
| WO2022254255A1 (en) | 2021-06-03 | 2022-12-08 | Fundacao D. Anna De Sommerchampalimaud E Dr. | Neuro-mesenchyme units control ilc2 and obesity via a brain-adipose circuit |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2225819T3 (es) | 1991-09-20 | 2005-03-16 | Amgen Inc. | Factor neurotrofico de origen glial. |
| US6184200B1 (en) | 1995-09-28 | 2001-02-06 | Amgen Inc. | Truncated glial cell line-derived neurotrophic factor |
| US6042579A (en) | 1997-04-30 | 2000-03-28 | Medtronic, Inc. | Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain |
| DE19816186A1 (de) * | 1998-04-14 | 1999-10-21 | Univ Muenchen L Maximilians | GDNF-kodierende DNA, Teile davon und GDNF-Varianten |
| US8946151B2 (en) | 2003-02-24 | 2015-02-03 | Northern Bristol N.H.S. Trust Frenchay Hospital | Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen |
| FI20070808A0 (fi) * | 2007-10-25 | 2007-10-25 | Mart Saarma | GDNF:n silmukointivariantit ja niiden käytöt |
| CN101775072B (zh) * | 2008-05-21 | 2012-09-05 | 王尚武 | 一种融合穿透肽的神经细胞营养因子gdnf |
| US8772236B2 (en) * | 2009-02-06 | 2014-07-08 | Pepscan Systems B.V. | Truncated cystine-knot proteins |
-
2012
- 2012-03-04 UA UAA201311714A patent/UA112981C2/uk unknown
- 2012-03-27 TW TW101110653A patent/TWI583698B/zh active
- 2012-04-03 ES ES12712874.2T patent/ES2656020T3/es active Active
- 2012-04-03 BR BR112013026004-1A patent/BR112013026004B1/pt not_active IP Right Cessation
- 2012-04-03 ME MEP-2017-276A patent/ME02849B/me unknown
- 2012-04-03 EP EP12712874.2A patent/EP2696889B1/en active Active
- 2012-04-03 AU AU2012243178A patent/AU2012243178B2/en not_active Ceased
- 2012-04-03 MX MX2013011919A patent/MX337206B/es active IP Right Grant
- 2012-04-03 US US14/000,704 patent/US9243046B2/en active Active
- 2012-04-03 SI SI201231134T patent/SI2696889T1/en unknown
- 2012-04-03 LT LTEP12712874.2T patent/LT2696889T/lt unknown
- 2012-04-03 HR HRP20171993TT patent/HRP20171993T1/hr unknown
- 2012-04-03 WO PCT/US2012/031927 patent/WO2012141936A1/en not_active Ceased
- 2012-04-03 RS RS20171274A patent/RS56639B1/sr unknown
- 2012-04-03 NO NO12712874A patent/NO2696889T3/no unknown
- 2012-04-03 EA EA201370204A patent/EA025129B1/ru not_active IP Right Cessation
- 2012-04-03 CA CA2833158A patent/CA2833158C/en not_active Expired - Fee Related
- 2012-04-03 HU HUE12712874A patent/HUE036239T2/hu unknown
- 2012-04-03 KR KR1020137026366A patent/KR101554799B1/ko not_active Expired - Fee Related
- 2012-04-03 SG SG2013069554A patent/SG193483A1/en unknown
- 2012-04-03 DK DK12712874.2T patent/DK2696889T3/en active
- 2012-04-03 JP JP2014505179A patent/JP6093345B2/ja active Active
- 2012-04-03 CN CN201280018010.7A patent/CN103635201B/zh active Active
- 2012-04-03 PT PT127128742T patent/PT2696889T/pt unknown
- 2012-04-03 PL PL12712874T patent/PL2696889T3/pl unknown
-
2013
- 2013-08-22 IL IL228102A patent/IL228102A/en active IP Right Grant
- 2013-08-30 ZA ZA2013/06556A patent/ZA201306556B/en unknown
-
2018
- 2018-01-09 CY CY20181100021T patent/CY1119750T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL262976A (en) | Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof | |
| NZ611878A (en) | Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides | |
| RU2016146801A (ru) | Вакцинная композиция против инфекции, вызванной streptococcus suis | |
| WO2009033751A3 (en) | Use of leu-enkephalin as a therapeutic agent | |
| WO2009033782A3 (en) | Use of a teprotide and optionally carbetocin to treat eg aids or idiopathic pulmonay fibrosis | |
| CA2703234C (en) | An inhalable dry powder formulation comprising glp-1 for use by pulmonary inhalation | |
| WO2009033783A3 (en) | Use of carbetocin to treat of eg aids or idiopathic pulmonary fibrosis | |
| JP2012041342A5 (enExample) | ||
| JP2016516016A5 (enExample) | ||
| WO2009046863A3 (en) | Use of thymosin alpha 1 peptide or the combination with the human pancreatic polypeptide as a therapeutic agent | |
| FI3482765T3 (fi) | Pitkävaikutteinen kasvuhormoni ja menetelmiä sen tuottamiseksi | |
| WO2009033789A3 (en) | Use of a peptide as a therapeutic agent | |
| RU2013139651A (ru) | Новые соединения, влияющие на пищевое поведение | |
| WO2009033760A3 (en) | Use of fibronectin fragment (196-203 ) as a therapeutic agent | |
| WO2009039974A3 (en) | Use of peptide asp-arg-gly-asp-ser-oh as a therapeutic agent | |
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| WO2009033737A3 (en) | Use of gluten exorphin c : as a therapeutic agent | |
| NZ599930A (en) | Pharmaceutical compositions for the stimulation of stem cells. | |
| WO2009039968A3 (en) | Use of angiotensin iii as a therapeutic agent in the treatment of eg hbv infection | |
| JP2014508734A5 (enExample) | ||
| NZ602693A (en) | Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae | |
| CN102643339A (zh) | 一种glp-1类似物、制备方法及其应用 | |
| JP2014506787A5 (enExample) | ||
| JP2015532293A5 (ja) | 糖尿病患者における心不全の治療用組成物 | |
| JP2020105169A5 (enExample) |